CTMX
Cytomx Therapeutics Inc
NASDAQ · Biotechnology
$5.67
+0.43 (+8.21%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 276.11M | 178.48M | 143.04M | 145.29M | 120.96M |
| Net Income | 63.72M | 37.07M | 18.37M | 18.60M | 11.33M |
| EPS | — | — | — | — | — |
| Profit Margin | 23.1% | 21.9% | 12.9% | 12.8% | 9.4% |
| Rev Growth | +54.7% | +54.7% | -6.3% | +5.8% | -7.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 237.52M | 261.90M | 281.15M |
| Total Equity | — | — | 557.97M | 637.36M | 662.84M |
| D/E Ratio | — | — | 0.43 | 0.41 | 0.42 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 53.13M | 32.63M | 25.12M | 25.56M | 23.91M |
| Free Cash Flow | — | — | 17.80M | 18.27M | 13.74M |